SNPS — Synopsys, Inc.

The August 26, 2026 Q3 beat was the catalyst: revenue of $2.477B beat the ~$2.44B consensus, non-GAAP EPS of $3.91 beat the $3.67 estimate, full-year revenue guidance was raised to $9.69-9.74B, and management said the Ansys integration is ahead of plan. That reversed a three-month de-rating caused by fears of core EDA deceleration, and analysts remain Buy-leaning with a consensus target of $554.22.

Revenue inflected sharply upward over the last 12 quarters: roughly flat at $1.45-1.64B through FY2024, then +14% Y/Y in Q3 FY2025, +38% in Q4 FY2025 after Ansys consolidated, and +42% in Q3 FY2026 to $2.48B. The acquisition caused the level shift, but the encouraging organic signals are EDA returning to double-digit growth, Design IP reaccelerating, and Q4 guidance implying even faster EDA growth. GAAP operating margin recovered from ~8.4% in Q1 FY2026 to 14.4% in Q3 FY2026, though it remains below the ~20-24% pre-acquisition level. TTM GAAP EPS of $5.62 is distorted by deal-related charges; the underlying non-GAAP earnings trajectory is far stronger.

At $464.89, the TTM P/E looks extreme at 192x, but that is mostly an accounting artifact of acquisition and amortization charges depressing GAAP EPS to $5.62. On the consensus EPS estimate of $14.78, the forward P/E is about 31.5x, well below the 5-year average P/E of 52.1x. Price-to-sales of 9.45x is also below the 5-year average of 11.65x. For a business with 40%+ reported growth and durable EDA moats, that is not expensive versus its own history, though it is still a premium absolute multiple.

The stock had de-rated from roughly $616 to $410 on concerns that core EDA was slowing; the Q3 print showed the opposite, and the 13.4% one-day jump was investors re-rating toward visible growth. As of 2026-08-27 the stock is still about 16% below the consensus target, so the market is not pricing in a flawless recovery. The bull case hinges on FY2027 showing continued double-digit organic growth after the Ansys lap; if growth instead stalls, owning a ~31.5x forward-earnings stock leaves limited room for error.

As of 2026-08-27, RSI is 71.7, which is overbought after the earnings gap, and price is +13.8% above its 20-day SMA, +11.4% above its 50-day SMA, and +4.1% above its 200-day SMA. This is a strong momentum breakout, but the vertical move suggests near-term consolidation risk; a pullback toward the 20-day or a cool-down in RSI would offer a better entry than chasing the spike. These levels are anchored to the analysis date and will have moved by the time this is read.

• AI silicon complexity — multi-die architectures, advanced packaging, and physical AI — is a structural tailwind for EDA and Ansys's simulation portfolio.
• Semiconductor design starts and R&D budgets remain healthy, but a sharp downturn in chip end-demand would hit EDA licensing and IP revenue.
• U.S.-China export controls and fragmenting supply chains limit the addressable market and raise compliance costs for a dominant U.S. EDA vendor.
• Long-term Treasury yields and tech-sector risk appetite still drive multiple expansion or compression for a ~31x forward-earnings stock.
• Competitive response from Cadence and Siemens EDA could pressure share gains in core EDA and multiphysics simulation.

• September 30, 2026 Analyst Day — expected detail on Multiphysics Fusion and Factory 2 could reset the long-term growth story.
• Q4 FY2026 earnings in late November/December 2026 — initial FY2027 guidance will test whether EDA acceleration can persist.
• Further Ansys synergy upside — management pulled cost synergies forward and raised the full-year Ansys revenue contribution to ~$2.98B.
• New AI/custom-silicon design wins translating into multi-year EDA and IP orders.

• Integration and execution risk on Ansys: long-term debt is $9.0B, and the balance-sheet step-up from acquisition accounting distorts reported returns and margins.
• Post-earnings technicals are stretched — RSI of 71.7 and +13.8% versus the 20-day SMA suggest a short-term pullback is possible even with an intact long-term thesis.
• China export controls and geopolitical decoupling could cap growth and create lumpy licensing outcomes.
• A high absolute multiple leaves the stock vulnerable if post-acquisition growth decelerates faster than expected.

Synopsys is a high-quality EDA franchise in the middle of a growth inflection: the Q3 FY2026 beat, full-year raise, and ahead-of-plan Ansys integration support the bull case, and the stock is still below both its 52-week high and the consensus target. It is not a low-risk bargain at ~31.5x forward earnings, but for a long-term investor the risk/reward is favorable — ideally entered on a technical pullback rather than after a 13% one-day spike.

Applied a 38.0x forward P/E multiple to the consensus EPS estimate of $14.78 from the data — a premium justified by strong secular growth, high gross margins, and the EDA oligopoly, but below the 5-year average P/E of 52.1x because post-Ansys growth will normalize and integration risk is real. This yields $561.56.